Safety and Efficacy of Fluoxetine in Pulmonary Arterial Hypertension

University of Texas Southwestern Medical Center6 enrolled

Overview

This study will evaluate the safety, tolerability and efficacy of open-label fluoxetine for three months among patients with pulmonary arterial hypertension.

Idiopathic pulmonary arterial hypertension (PAH) is a life-threatening disorder of uncertain cause that leads to progressive right heart failure and death. Average survival has improved from about 2.8 years in the early 1990s to approximately 5-7 years with current treatments, but most patients will still die of their disease. Two classes of oral medications are approved for use in PAH: endothelin-1 antagonists, and phosphodiesterase-5 inhibitors. Both improve walk distance and symptoms in PAH, but most patients still have continued dyspnea, fatigue and significant elevations in pulmonary pressures. Those who remain severely impaired are generally started on a continuous intravenous prostacyclin. For those who are less ill but still symptomatic, few options are available. Primary endpoint: the primary endpoint will be change in pulmonary vascular resistance (PVR) measured by right heart catheterization after three months of therapy. Secondary endpoints * Six minute walk distance * QIDS-SR depression scale Safety and tolerability endpoints will include a tabulation of adverse events to include but not limited to: * Death * Hospitalization * Symptomatic hypotension * Gastrointestinal side effects * Depression

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Pulmonary Arterial Hypertension

Interventions

FluoxetineDRUG

Total dose How to take: Week 1-2 20 mg daily Week 3-4 40 mg daily Week 5-6 40 mg BID Week 7-12 40mg BID

Eligibility

Sex: ALLMin age: 16 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Signed informed consent prior to any study-mandated procedure 2. PAH of the following subtypes: idiopathic PAH WHO functional class II-III 3. Catheterization within one week showing mPAP \>=25, wedge or LV end diastolic pressure ≤15, and PVR \> 4 wood units, and baseline fick cardiac output results available 4. Age 16-75 5. Able to complete a six minute walk distance 6. Women of childbearing potential\*: negative serum pre-treatment pregnancy test + consistently and correctly uses a reliable method of contraception\*\* Oral approved PAH therapy for \>3 months with no change in dose for \> 1 month Exclusion Criteria: 1. PAH with connective tissue disease, congenital heart disease, portal hypertension, glycogen storage disease, Gaucher's disease, hereditary hemorrhagic telangiectasia, hemoglobinopathy, myeloproliferative disorders. 2. Moderate to severe obstructive or restrictive lung disease: forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) \< 70% and FEV1 \< 60% of predicted value after bronchodilator administration. -or- total lung capacity (TLC) \< 60% of predicted. 3. Systemic systolic blood pressure \<100 mmHg Breastfeeding 4. Significant liver, renal or other medical disease preventing completion of the study procedures or with life expectancy \<12 months, or any other acute or chronic physical impairment (other than dyspnea), limiting the ability to comply with study requirements

Locations (1)

UT Southwestern Medical Center

Dallas, Texas, United States

Outcomes

Primary Outcomes

Change in Pulmonary Vascular Resistance (PVR) at Three Months

PVR will be measured by right heart catheterization at baseline and 3 months. Change in PVR will be determined by baseline value minus 3 month value.

Time frame: Change in PVR at 3 mos (Baseline - 3 months)

Secondary Outcomes

Change Between Baseline and Three Month in the QIDS-SR Depression Scale

The Quick Inventory of Depressive Symptomatology Self Report (QIDS-SR) depression scale is a questionnaire completed by the patient. Lower scores are better. Scoring can be interpreted as 7 or less: normal, 8-12: mild depression, 13-16 moderate depression, 17-20 moderate to severe depression and \>20 severe depression. Results here show the median change between baseline and 3 months, making a positive change in score indicative of improvement. Total minimum score is 0 and the maximum is 27.

Time frame: Baseline - 3 months (median change)

Change in Six Minute Walk Distance at 3 Months

Six minute walk distance will be measured at baseline and after 3 months of fluoxetine. Change in walk distance (mean and SD) will be reported by taking subtracting baseline values from result at 3 months.

Time frame: 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.